RLAY News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RL

Mkt Cap

$3.57B

Volume

1.85M

Next Earnings

November 5th

Loading chart

RL

RLAYRelay Therapeutics, Inc. Common Stock

RLAY

Pay with—

Available Balance0.00

RL

Mkt Cap

$3.57B

Volume

1.85M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Elevar Therapeutics Announces FDA Approval of Lyrfigtu (Lirafugratinib) as Second-line Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment OptionElevar Therapeutics announced FDA approval of Lyrfigtu (lirafugratinib) for treating cholangiocarcinoma patients with FGFR2 fusion or rearrangement. The drug demonstrated a 46% objective response rate and 11.8-month median duration of response in the Phase 1/2 ReFocus trial. Lyrfigtu is expected to be available in the U.S. by Q4 2026 and represents a second-line treatment option for this rare bile duct cancer.GlobeNewswire Inc. · Sep 23, 2026

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberRelay Therapeutics announced that management will participate in fireside chats at the Wells Fargo Healthcare Conference on September 8, 2026 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. The clinical-stage precision medicine company is developing therapies for cancer and genetic diseases, with its lead asset zovegalisib currently in Phase 3 trials for HR+/HER2- metastatic breast cancer.GlobeNewswire Inc. · Sep 1, 2026

Is Relay Therapeutics a Buy After Promising Trial Results?Relay Therapeutics announced promising phase 2 trial results for zovegalisib in treating vascular anomalies, with a 60% volumetric response rate. The clinical-stage biotech has a well-capitalized position with $642 million in cash, a structured path to market including a planned phase 3 trial in early 2027, and a diversified pipeline. However, as a pre-revenue company, it faces significant binary risk dependent on the clinical and regulatory success of its lead therapy.The Motley Fool · May 22, 2026

Relay Therapeutics Announces Pricing of Public Offering of Common StockRelay Therapeutics priced an underwritten public offering of 22.9 million shares at $12.00 per share, raising approximately $275 million in gross proceeds. The offering is expected to close on May 22, 2026. The clinical-stage biotech company is developing precision medicine therapies, with its lead asset zovegalisib currently in Phase 3 trials for HR+/HER2- metastatic breast cancer and being investigated for PIK3CA-driven vascular anomalies.GlobeNewswire Inc. · May 21, 2026

Why Relay Therapeutics Stock Popped on WednesdayRelay Therapeutics stock surged 7.87% on Wednesday following positive Phase 2 results for zovegalisib, a vascular anomalies treatment, which showed 60% patient response rates at 12 weeks—exceeding analyst expectations. Two analysts raised their price targets (Barclays to $27, Citizens JMP to $21) and maintained buy ratings. The gains were partially offset by the company's announcement of a secondary stock offering exceeding $200 million.The Motley Fool · May 20, 2026

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular AnomaliesRelay Therapeutics announced promising Phase 2 clinical data for zovegalisib in treating PIK3CA-driven vascular anomalies, demonstrating a 60% volumetric response rate at 12 weeks with strong safety and tolerability profiles supporting chronic dosing. The drug showed clinical improvement in 89% of patients per investigator assessment and 79% per patient assessment, with no treatment discontinuations due to adverse events. Expansion cohorts have opened at 400mg once daily and 300mg twice daily doses.GlobeNewswire Inc. · May 19, 2026

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast CancerRelay Therapeutics announced positive clinical data for zovegalisib combined with Pfizer's atirmociclib and endocrine therapy in heavily pre-treated metastatic breast cancer patients, showing 44% ORR with favorable tolerability. The company plans to initiate a Phase 3 frontline trial in early 2027 with a supply agreement in place with Pfizer for atirmociclib.GlobeNewswire Inc. · Apr 27, 2026

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.Nextech Invest, a Switzerland-based biotech-focused fund, increased its stake in Relay Therapeutics by 855,097 shares (~$6.1 million). The purchase brings Relay to 3.85% of Nextech's portfolio. Relay's stock has surged 197% over the past year, driven by its computational drug discovery platform and clinical-stage pipeline including lead candidates RLY-4008 and RLY-2608.The Motley Fool · Mar 19, 2026

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 MillionCommodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has a strong balance sheet with $757 million in cash and expects runway into H2 2028, with six Phase 2 readouts expected in 2026.The Motley Fool · Feb 23, 2026

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%Commodore Capital reduced its Nuvalent stake by 850,000 shares (worth $83.81 million) in Q4 2025, cutting the position from 9.26% to 3.68% of assets. Despite the sale, Nuvalent shares are up 29% over the past year and the company maintains strong cash runway into 2029 with upcoming FDA catalysts including a PDUFA date for zidesamtinib in September.The Motley Fool · Feb 23, 2026

to start trading

RL

RLAYRelay Therapeutics, Inc. Common Stock

RLAY

Pay with—

Available Balance0.00

Your PositionYou don't own any RLAY yet.

Related Tickers

Earnings